Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	12	APR 26	PROMT: New display field available
NEWS	13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	14	APR 26	LITALERT now available on STN
NEWS	15	APR 27	NLDB: New search and display fields available
NEWS	16	May 10	PROUSDDR now available on STN
NEWS	17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS	18	May 12	EXTEND option available in structure searching
NEWS	19	May 12	Polymer links for the POLYLINK command completed in REGISTRY

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

Patel <5/14/2004>

FILE 'HOME' ENTERED AT 07:56:03 ON 14 MAY 2004

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:56:29 ON 14 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAY 2004 HIGHEST RN 681425-81-0
DICTIONARY FILE UPDATES: 12 MAY 2004 HIGHEST RN 681425-81-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10087717.15

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 07:57:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 474 TO ITERATE

100.0% PROCESSED 474 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L2 2 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'CAPLUS' ENTERED AT 07:57:15 ON 14 MAY 2004

Patel <5/14/2004>

FILE COVERS 1907 - 14 May 2004 VOL 140 ISS 21
FILE LAST UPDATED: 13 May 2004 (20040513/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 1 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:695962 CAPLUS
DN 137:232680
TI Preparation of aryl and heteroaryl urea selective Chk1 inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication
IN Keegan, Kathleen S.; Kesicki, Edward A.; Gaudino, John Joseph; Cook, Adam Wade; Cowen, Scott Douglas; Burgess, Laurence Edward
PA Icos Corporation, USA
SO PCT Int. Appl., 236 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070494	A1	20020912	WO 2002-US6452	20020301
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-273124PP	20010302
	US 2003069284	A1	20030410	US 2002-87715	20020301
				US 2001-273124PP	20010302
	EP 1379510	A1	20040114	EP 2002-728396	20020301
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2001-273124PP	20010302
				WO 2002-US6452 W	20020301
	NO 2003003858	A	20031010	NO 2003-3858	20030901
				US 2001-273124PP	20010302
				WO 2002-US6452 W	20020301

OS MARPAT 137:232680
IT **457098-89-4P**, 1-(5-Methylpyrazin-2-yl)-3-[5-methyl-2-(1,2,3,4-tetrahydroquinolin-3-ylmethoxy)phenyl]urea **457099-03-5P**, 1-[5-Methyl-2-(piperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl and heteroaryl urea selective Chk1 inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and

conditions related to DNA damage or lesions in DNA replication)

RN 457098-89-4 CAPLUS
CN Urea, N-(5-methylpyrazinyl)-N'-[5-methyl-2-[(1,2,3,4-tetrahydro-3-quinolinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 457099-03-5 CAPLUS
CN Urea, N-[5-methyl-2-(3-piperidinylmethoxy)phenyl]-N'-(5-methylpyrazinyl)- (9CI) (CA INDEX NAME)



AB Aryl- and heteroaryl substituted urea compds. (W'NHC(:Y')N(R13)Z'; 1) useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. In 1, W' is a six-membered aromatic ring containing at least 2 nitrogen atoms (e.g. pyrazinyl, pyrimidinyl, pyridazinyl, 1,2,4-triazinyl, quinoxalinyl) and optionally substituted as defined in the claims, Z' is a five- or six membered aromatic or heteroarom. ring as defined in the claims, Y' is O or S. The first claim contains a much more general formula WX1C(:Y)X2Z (e.g. X1 = null, O, S, CH2, NR1; X2 = O, S, NR1) but emphasis is on 1. Methods of making the compds., and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are described. Although the methods of preparation are not claimed, about 200 example prepns. are included. N-(2-methoxy-5-methylphenyl)-N'-(2-pyrazinyl)urea and N-(4-chloro-2-methoxyphenyl)-N'-(2-pyrazinyl)urea enhanced the killing of various human cells by 5-fluorouracil from 2- to 10-fold; in HeLa cells, these same compds. enhanced killing by irradiation 2-3 fold.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.19	160.82

Patel <5/14/2004>

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.69	-0.69

STN INTERNATIONAL LOGOFF AT 07:57:53 ON 14 MAY 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 5	FEB 05	German (DE) application and patent publication number format changes
NEWS 6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 8	MAR 03	FRANCEPAT now available on STN
NEWS 9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS 10	MAR 29	WPIFV now available on STN
NEWS 11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 12	APR 26	PROMT: New display field available
NEWS 13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS 14	APR 26	LITALERT now available on STN
NEWS 15	APR 27	NLDB: New search and display fields available
NEWS 16	May 10	PROUSDDR now available on STN
NEWS 17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS 18	May 12	EXTEND option available in structure searching
NEWS 19	May 12	Polymer links for the POLYLINK command completed in REGISTRY

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

Patel <5/14/2004>

FILE 'HOME' ENTERED AT 08:03:49 ON 14 MAY 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:04:00 ON 14 MAY 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAY 2004 HIGHEST RN 681425-81-0
DICTIONARY FILE UPDATES: 12 MAY 2004 HIGHEST RN 681425-81-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10087715.16

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 N,NH,NH2,Cb,Cy,Hy

Patel <5/14/2004>

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 08:04:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 118 TO ITERATE

100.0% PROCESSED 118 ITERATIONS 70 ANSWERS
SEARCH TIME: 00.00.01

L2 70 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'CAPLUS' ENTERED AT 08:04:34 ON 14 MAY 2004

FILE COVERS 1907 - 14 May 2004 VOL 140 ISS 21
FILE LAST UPDATED: 13 May 2004 (20040513/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 1 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:695962 CAPLUS
DN 137:232680
TI Preparation of aryl and heteroaryl urea selective Chk1 inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication
IN Keegan, Kathleen S.; Kesicki, Edward A.; Gaudino, John Joseph; Cook, Adam Wade; Cowen, Scott Douglas; Burgess, Laurence Edward
PA Icos Corporation, USA
SO PCT Int. Appl., 236 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070494	A1	20020912	WO 2002-US6452	20020301
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-273124PP	20010302
	US 2003069284	A1	20030410	US 2002-87715	20020301
				US 2001-273124PP	20010302
	EP 1379510	A1	20040114	EP 2002-728396	20020301
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2001-273124PP	20010302
				WO 2002-US6452 W	20020301
	NO 2003003858	A	20031010	NO 2003-3858	20030901
				US 2001-273124PP	20010302
				WO 2002-US6452 W	20020301

OS MARPAT 137:232680

IT **457096-87-6P**, N-Benzyl-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide **457096-89-8P**, 3-Methoxy-N-phenethyl-4-(3-(pyrazin-2-yl)ureido)benzamide **457096-90-1P**, 3-Methoxy-N-(3-phenylpropyl)-4-(3-(pyrazin-2-yl)ureido)benzamide **457096-95-6P**, N-(4-Iodobenzyl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide **457096-97-8P 457096-99-0P**, 3-Methoxy-4-(3-(pyrazin-2-yl)ureido)-N-(2-(pyridin-4-yl)ethyl)benzamide **457097-01-7P**, N-(1H-Benzimidazol-2-ylmethyl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-04-0P 457097-05-1P**, 3-Methoxy-N-[3-(methylphenylamino)propyl]-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-08-4P 457097-10-8P**, N-((3R)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-13-1P**, N-((3S)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-18-6P**, 3-Methoxy-N-(3-methylaminopropyl)-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-21-1P**, N-(3-Dimethylaminopropyl)-3-methoxy-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-25-5P**, 3-Methoxy-N-(3-(morpholin-4-yl)propyl)-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-27-7P**, 3-Methoxy-N-[3-(4-methylpiperazin-1-yl)propyl]-4-(3-(pyrazin-2-yl)ureido)benzamide **457097-29-9P**, [2-[3-Methoxy-4-(3-(pyrazin-2-yl)ureido)benzoylamino]ethyl]trimethylammonium chloride **457097-36-8P**, N-Benzyl-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-37-9P**, 4-Methoxy-N-phenethyl-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-38-0P**, 4-Methoxy-N-(3-phenylpropyl)-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-40-4P**, 4-Methoxy-3-(3-(pyrazin-2-yl)ureido)-N-(2-(pyridin-2-yl)ethyl)benzamide **457097-41-5P**, 4-Methoxy-3-(3-(pyrazin-2-yl)ureido)-N-(2-(pyridin-4-yl)ethyl)benzamide **457097-42-6P**, N-(1H-Benzimidazol-2-ylmethyl)-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-43-7P**, N-[2-(1H-Indol-3-yl)ethyl]-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-44-8P**, 4-Methoxy-N-[3-(methylphenylamino)propyl]-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-45-9P 457097-47-1P**,

4-Methoxy-N-(3-methylaminopropyl)-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-48-2P**, N-(3-Dimethylaminopropyl)-4-methoxy-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-50-6P**, 4-Methoxy-N-[3-(4-methylpiperazin-1-yl)propyl]-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-51-7P**, [2-[4-Methoxy-3-(3-(pyrazin-2-yl)ureido)benzoylamino]ethyl]trimethylammonium chloride **457097-52-8P**, 4-Methoxy-N-(3-(morpholin-4-yl)propyl)-3-(3-(pyrazin-2-yl)ureido)benzamide **457097-57-3P**, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(2-(pyridin-2-yl)ethyl)benzamide **457097-59-5P**, N-(1-Benzylpiperidin-4-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457097-61-9P**, N-(3-Dimethylaminopropyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457097-63-1P**, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(3-(morpholin-4-yl)propyl)benzamide **457097-65-3P**, N-(2-(Dimethylamino)-2-phenylethyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457097-68-6P**, N-(2-(Dimethylamino)-1-phenylethyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457097-70-0P**, N-(1-Azabicyclo[2.2.2]oct-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457097-71-1P**, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3R)-1-(pyridin-2-yl)methylpyrrolidin-3-yl)benzamide **457097-74-4P**, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3R)-1-methylpyrrolidin-3-yl)benzamide **457097-76-6P**, N-((3R)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457097-77-7P**, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3R)-1-[(pyridin-4-yl)methyl]pyrrolidin-3-yl)benzamide **457097-79-9P**, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3S)-1-[(thiophen-2-yl)methyl]pyrrolidin-3-yl)benzamide **457097-81-3P**, N-((3R)-1-Cyclohexylmethylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457097-83-5P**, N-((3S)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457097-84-6P**, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3S)-1-[(pyridin-2-yl)methyl]pyrrolidin-3-yl)benzamide **457097-86-8P**, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3S)-1-[(pyridin-3-yl)methyl]pyrrolidin-3-yl)benzamide **457097-87-9P**, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3S)-1-[(pyridin-4-yl)methyl]pyrrolidin-3-yl)benzamide **457097-90-4P**, N-((3S)-1-Cyclohexylmethylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457097-92-6P**, N-((3S)-1-Benzylpyrrolidin-3-yl)-4-[3-(5-methylpyrazin-2-yl)ureido]-3-trifluoromethoxybenzamide **457097-97-1P**, N-(1-Benzylpiperidin-4-ylmethyl)-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457097-98-2P**, N-[(3S)-1-(4-Fluorobenzyl)pyrrolidin-3-yl]-3-methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457098-04-3P**, N-((3S)-1-Benzylpyrrolidin-3-yl)-3-methoxy-4-[3-(5-trifluoromethylpyrazin-2-yl)ureido]benzamide **457098-08-7P**, 5-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(2-(pyridin-2-yl)ethyl)-2-trifluoromethylbenzamide **457098-23-6P**, N-Benzyl-3-(3-dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457098-25-8P**, 3-(3-Dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]-N-(2-(morpholin-4-yl)ethyl)benzamide **457098-26-9P**, 3-(3-Dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]-N-[2-(1-methylpyrrolidin-2-yl)ethyl]benzamide **457098-27-0P**, N-(2-Dimethylaminoethyl)-3-(3-dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457098-28-1P**, N-((3S)-1-Benzylpyrrolidin-3-yl)-3-(3-dimethylaminopropoxy)-4-[3-(5-methylpyrazin-2-yl)ureido]benzamide **457098-32-7P**, N-Benzyl-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide **457098-34-9P**, 4-[3-(5-Methylpyrazin-2-

yl)ureido]-N-(2-(morpholin-4-yl)ethyl)-3-(pyridin-3-ylmethoxy)benzamide **457098-35-0P**, 4-[3-(5-Methylpyrazin-2-yl)ureido]-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-3-(pyridin-3-ylmethoxy)benzamide **457098-36-1P**, N-(2-Dimethylaminoethyl)-4-[3-(5-methylpyrazin-2-yl)ureido]-3-(pyridin-3-ylmethoxy)benzamide **457098-37-2P** **457099-93-3P**, N-(2-Methoxy-3-((2-(4-morpholinyl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea **457099-94-4P**, N-(2-Methoxy-3-((2-(1-methylpyrrolidin-2-yl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea **457099-96-6P**, N-(2-Methoxy-4-((2-(4-morpholinyl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea **457099-97-7P**, N-(2-Methoxy-4-((2-(1-methylpyrrolidin-2-yl)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea **457099-98-8P**, N-(2-Methoxy-4-((2-((methylsulfonyl)amino)ethyl)carbamoyl)phenyl)-N'-(2-pyrazinyl)urea **458523-51-8P**, 3-Methoxy-4-[3-(5-methylpyrazin-2-yl)ureido]-N-((3R)-1-[(thiophen-2-yl)methyl]pyrrolidin-3-yl)benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl and heteroaryl urea selective Chk1 inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication)

RN 457096-87-6 CAPLUS
CN Benzamide, 3-methoxy-N-(phenylmethyl)-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457096-89-8 CAPLUS
CN Benzamide, 3-methoxy-N-(2-phenylethyl)-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457096-90-1 CAPLUS
CN Benzamide, 3-methoxy-N-(3-phenylpropyl)-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457096-95-6 CAPLUS
CN Benzamide, N-[(4-iodophenyl)methyl]-3-methoxy-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457096-97-8 CAPLUS
CN Benzamide, 3-methoxy-4-[[(pyrazinylamino)carbonyl]amino]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 457096-99-0 CAPLUS
CN Benzamide, 3-methoxy-4-[[(pyrazinylamino)carbonyl]amino]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 457097-01-7 CAPLUS
CN Benzamide, N-(1H-benzimidazol-2-ylmethyl)-3-methoxy-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-04-0 CAPLUS
CN Benzamide, N-[2-(1H-indol-3-yl)ethyl]-3-methoxy-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-05-1 CAPLUS
CN Benzamide, 3-methoxy-N-[3-(methylphenylamino)propyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-08-4 CAPLUS
CN Benzamide, 3-methoxy-N-[1-(phenylmethyl)-3-pyrrolidinyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 457097-10-8 CAPLUS
CN Benzamide, 3-methoxy-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457097-13-1 CAPLUS
CN Benzamide, 3-methoxy-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457097-18-6 CAPLUS
CN Benzamide, 3-methoxy-N-[3-(methylamino)propyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-21-1 CAPLUS
CN Benzamide, N-[3-(dimethylamino)propyl]-3-methoxy-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-25-5 CAPLUS
CN Benzamide, 3-methoxy-N-[3-(4-morpholinyl)propyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-27-7 CAPLUS
CN Benzamide, 3-methoxy-N-[3-(4-methyl-1-piperazinyl)propyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-29-9 CAPLUS
CN Ethanaminium, 2-[[3-methoxy-4-[[(pyrazinylamino)carbonyl]amino]benzoyl]amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



RN 457097-36-8 CAPLUS
CN Benzamide, 4-methoxy-N-(phenylmethyl)-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



Patel

<5/14/2004>

RN 457097-37-9 CAPLUS
CN Benzamide, 4-methoxy-N-(2-phenylethyl)-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-38-0 CAPLUS
CN Benzamide, 4-methoxy-N-(3-phenylpropyl)-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-40-4 CAPLUS
CN Benzamide, 4-methoxy-3-[[(pyrazinylamino)carbonyl]amino]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 457097-41-5 CAPLUS
CN Benzamide, 4-methoxy-3-[[(pyrazinylamino)carbonyl]amino]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 457097-42-6 CAPLUS
CN Benzamide, N-(1H-benzimidazol-2-ylmethyl)-4-methoxy-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-43-7 CAPLUS
CN Benzamide, N-[2-(1H-indol-3-yl)ethyl]-4-methoxy-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-44-8 CAPLUS
CN Benzamide, 4-methoxy-N-[3-(methylphenylamino)propyl]-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-45-9 CAPLUS
CN Benzamide, 4-methoxy-N-[1-(phenylmethyl)-3-pyrrolidinyl]-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-47-1 CAPLUS
CN Benzamide, 4-methoxy-N-[3-(methylamino)propyl]-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-48-2 CAPLUS
CN Benzamide, N-[3-(dimethylamino)propyl]-4-methoxy-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-50-6 CAPLUS
CN Benzamide, 4-methoxy-N-[3-(4-methyl-1-piperazinyl)propyl]-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-51-7 CAPLUS
CN Ethanaminium, 2-[[4-methoxy-3-[[(pyrazinylamino)carbonyl]amino]benzoyl]amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



RN 457097-52-8 CAPLUS
CN Benzamide, 4-methoxy-N-[3-(4-morpholinyl)propyl]-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-57-3 CAPLUS
CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 457097-59-5 CAPLUS
CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

Patel <5/14/2004>



RN 457097-61-9 CAPLUS
CN Benzamide, N-[3-(dimethylamino)propyl]-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-63-1 CAPLUS
CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 457097-65-3 CAPLUS
CN Benzamide, N-[2-(dimethylamino)-2-phenylethyl]-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-68-6 CAPLUS
CN Benzamide, N-[2-(dimethylamino)-1-phenylethyl]-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-70-0 CAPLUS
CN Benzamide, N-1-azabicyclo[2.2.2]oct-3-yl-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457097-71-1 CAPLUS
CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3R)-1-(2-pyridinylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457097-74-4 CAPLUS
CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3R)-1-methyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457097-76-6 CAPLUS
CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457097-77-7 CAPLUS
CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3R)-1-(4-pyridinylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457097-79-9 CAPLUS
CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3S)-1-(2-thienylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457097-81-3 CAPLUS
CN Benzamide, N-[(3R)-1-(cyclohexylmethyl)-3-pyrrolidinyl]-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457097-83-5 CAPLUS
CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457097-84-6 CAPLUS
CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3S)-1-(2-pyridinylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457097-86-8 CAPLUS
CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3S)-1-(3-pyridinylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457097-87-9 CAPLUS
CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3S)-1-(4-pyridinylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Patel <5/14/2004>

Absolute stereochemistry.



RN 457097-90-4 CAPLUS
CN Benzamide, N-[(3S)-1-(cyclohexylmethyl)-3-pyrrolidinyl]-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457097-92-6 CAPLUS
CN Benzamide, 4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457097-97-1 CAPLUS
CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[[1-

(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 457097-98-2 CAPLUS
CN Benzamide, N-[(3S)-1-[(4-fluorophenyl)methyl]-3-pyrrolidinyl]-3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457098-04-3 CAPLUS
CN Benzamide, 3-methoxy-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]-4-[[[[5-(trifluoromethyl)pyrazinyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457098-08-7 CAPLUS
CN Benzamide, 5-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[2-(2-

pyridinyl)ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 457098-23-6 CAPLUS
CN Benzamide, 3-[3-(dimethylamino)propoxy]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 457098-25-8 CAPLUS
CN Benzamide, 3-[3-(dimethylamino)propoxy]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 457098-26-9 CAPLUS
CN Benzamide, 3-[3-(dimethylamino)propoxy]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 457098-27-0 CAPLUS
CN Benzamide, N-[2-(dimethylamino)ethyl]-3-[3-(dimethylamino)propoxy]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457098-28-1 CAPLUS
CN Benzamide, 3-[3-(dimethylamino)propoxy]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457098-32-7 CAPLUS
CN Benzamide, 4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-(phenylmethyl)-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



RN 457098-34-9 CAPLUS
CN Benzamide, 4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[2-(4-morpholinyl)ethyl]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



RN 457098-35-0 CAPLUS
CN Benzamide, 4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



RN 457098-36-1 CAPLUS
CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



RN 457098-37-2 CAPLUS
CN Benzamide, 4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]-3-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 457099-93-3 CAPLUS
CN Benzamide, 2-methoxy-N-[2-(4-morpholinyl)ethyl]-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457099-94-4 CAPLUS
CN Benzamide, 2-methoxy-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-3-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457099-96-6 CAPLUS
CN Benzamide, 3-methoxy-N-[2-(4-morpholinyl)ethyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457099-97-7 CAPLUS
CN Benzamide, 3-methoxy-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 457099-98-8 CAPLUS
CN Benzamide, 3-methoxy-N-[2-[(methylsulfonyl)amino]ethyl]-4-[[(pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458523-51-8 CAPLUS
CN Benzamide, 3-methoxy-4-[[[(5-methylpyrazinyl)amino]carbonyl]amino]-N-[(3R)-1-(2-thienylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Aryl- and heteroaryl substituted urea compds. (W'NHC(:Y')N(R13)Z'; 1) useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. In 1, W' is a six-membered aromatic ring containing at least 2 nitrogen atoms (e.g. pyrazinyl, pyrimidinyl, pyridazinyl, 1,2,4-triazinyl, quinoxalinyl) and optionally substituted as defined in the claims, Z' is a five- or six membered aromatic or heteroarom. ring as defined in the claims, Y' is O or S. The first claim contains a much more general formula WX1C(:Y)X2Z (e.g. X1 = null, O, S, CH2, NR1; X2 = O, S, NR1) but emphasis is on 1. Methods of making the compds., and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are described. Although the methods of preparation are not claimed, about 200 example prepns. are included. N-(2-methoxy-5-methylphenyl)-N'-(2-pyrazinyl)urea and N-(4-chloro-2-methoxyphenyl)-N'-(2-pyrazinyl)urea enhanced the killing of various human cells by 5-fluorouracil from 2- to 10-fold; in HeLa cells, these same compds. enhanced killing by irradiation 2-3 fold.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.19	160.82
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.69	-0.69

FILE 'CAOLD' ENTERED AT 08:05:17 ON 14 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate

Patel <5/14/2004>

substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGistRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

```
=> s l2 sss full
L4              0 L2

=> file marpat
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               0.42     161.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00      -0.69

FILE 'MARPAT' ENTERED AT 08:05:34 ON 14 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 19)(20040507/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US     6716820 06 APR 2004
DE    20315397 01 APR 2004
EP     1403358 31 MAR 2004
JP 2004107291 08 APR 2004
WO 2004029058 08 APR 2004

Structure search limits have been raised. See HELP SLIMIT for the new,
higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 08:05:42 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -   5532 TO ITERATE

 90.0% PROCESSED    4977 ITERATIONS                          5 ANSWERS

100.0% PROCESSED    5532 ITERATIONS                          7 ANSWERS
SEARCH TIME: 00.00.31

L5              7 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             109.42     270.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
```

Patel <5/14/2004>

	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.69

FILE 'CAPLUS' ENTERED AT 08:06:21 ON 14 MAY 2004

FILE COVERS 1907 - 14 May 2004 VOL 140 ISS 21
FILE LAST UPDATED: 13 May 2004 (20040513/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l5
L6 7 L5

=> d l6 fbib hitstr abs total

L6 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:991345 CAPLUS
DN **140:42216**
TI Preparation of phenol or phenyl acetate derivatives for treatment of allergic diseases
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design. Inc., Japan
SO PCT Int. Appl., 418 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003103665	A1	20031218	WO 2003-JP7120	20030605

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2002-165148 A 20020606

OS MARPAT 140:42216
GI



I

AB The title compds. I [wherein X = a connecting group; A = H or acetyl; E = (un)substituted aryl or heteroaryl; ring Z = (un)substituted arene or heteroarene] and pharmaceutically acceptable salts, hydrates, and solvates thereof are prepared for the treatment of allergic diseases, endometriosis, and/or hysteromyoma (no data). A total of .apprx.500 I including N-phenylhydroxybenzamides (N-phenylsalicylamide), N-heterocyclylhydroxybenzamides, N-phenylhydroxycarbazolecarboxamides, N-phenylhydroxynaphthalenecarboxamides, N-phenylhydroxypyridinecarboxamides, N-phenylhydroxyquinoxalinecarboxamide, and N-phenylhydroxyindolecarboxamide were prepared The compds. I exhibited inhibitory activities against IgE production, cell proliferation, and cell degranulation.

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:971881 CAPLUS
DN **140:16750**
TI Preparation of diarylureas as Chk-1 kinase inhibitors for the treatment of cancer
IN Boyle, Robert George; Imogai, Hassan Julien; Cherry, Michael
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003101444	A1	20031211	WO 2003-US16677	20030528
WO 2003101444	C1	20040226		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-384207PP	20020529
			US 2002-432796PP	20021212
US 2004014765	A1	20040122	US 2003-446627	20030528
			US 2002-384207PP	20020529
			US 2002-432796PP	20021212

Patel <5/14/2004>

OS MARPAT 140:16750
GI



I

AB Disclosed are novel diarylurea inhibitors of Chk-1 (shown as I; variables defined below; e.g. 1-[5-chloro-2-(3-dimethylaminopropoxy)phenyl]-3-pyrazin-2-ylurea) and methods of using the same for treatment of cancer. Although the methods of preparation are not claimed, .apprx.40 example prepns. are included. For example, 1-[5-chloro-2-(2-dimethylaminoethoxy)phenyl]-3-pyrazin-2-ylurea was prepared starting from 2-amino-4-chlorophenol and N-(2-chloroethyl)dimethylamine hydrochloride to give [5-chloro-2-(2-dimethylaminoethoxy)phenyl]amine (72 %) followed by its reaction with pyrazine-2-carbonyl azide (prepared from pyrazine-2-carboxylic acid and diphenylphosphoryl azide (78 %)) with 83 % yield. Inhibitory activity towards Chk-1 kinase is tabulated for .apprx.30 examples of I, e.g. IC50 = 0.0025 μM for 1-[2-(3-aminopropoxy)-5-chlorophenyl]-3-pyrazin-2-ylurea. The ability of .apprx.11 examples of I to enhance the DNA damaging ability of camptothecins, 5-fluorouracil or etoposid is tabulated; e.g. 2.7-fold enhancement for 78 nM 1-[5-chloro-2-(3-aminopropoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea. For I: X1-X3 = CH or N, provided that X1-X3 are not all N; X4 is CH or N; Z is O, S, or N-CN; Ring A is (un)substituted at any substitutable C by R4; R1 is -T-NH2, -V-T-NH2, -T-NHRx, -V-T-NHRx; T is a C1-6 straight or branched alkylidene chain that is optionally interrupted by -O-, -S-, -N(R5)-, -S(O)-, -SO2-, -C(O)-, -OC(O)-, -N(R5)C(O)-, -C(O)N(R5)-, -SO2N(R5)-, or -N(R5)SO2-, wherein the alkylidene chain or a portion thereof is optionally part of a 3-6 membered ring system. V is -O-, -S-, -N(R5)-, -S(O)-, -SO2-, -C(O)-, -OC(O)-, -N(R5)C(O)-, -C(O)N(R5)-, -SO2N(R5)-, or -N(R5)SO2-; R2 and R3 = H, C1-6-alkyl (un)substituted with -N(R8)2, -C(O)R, -CO2R, or SO2R, or R2 and R3 taken together with their intervening atoms form an (un)substituted 5-6 membered ring; each R4 = halo, -OR, -SR, -CN, -NO2, -N(R5)2, -N(R5)C(O)R, -N(R5)CO2R, -N(R5)C(O)N(R5)2, -C(O)N(R5)2, -C(O)R5, -OC(O)N(R5)2, -CO2R, -SO2R, -S(O)R, -SO2N(R5)2, -N(R5)SO2R, or an (un)substituted C1-8 aliphatic, aryl, aralkyl, heterocyclyl, heterocyclealkyl, heteroaryl, or heteroaralkyl, or two ortho R4s, taken together with the ortho C atoms to which they are bonded, form an (un)substituted five or six membered Ph, pyridyl or heterocyclyl fused to Ring A. Each R5 = H, C1-6 aliphatic, -CO2R, -SO2R, or -C(O)R, or two R5 on the same N taken together with the N form a 5-8 membered heteroaryl or heterocycle ring having 1-4 heteroatoms = N, O, or S; each R8 = a C1-3-alkyl or, taken together with the N atom to which they are bonded, a 5-7 membered N containing heterocycle; Ring D is (un)substituted by C1-4 aliphatic or haloaliph., -OR7, -SR7, -C(O)R7, -CO2R7, -SO2R7, -CN, -C(O)N(R7)2, -N(R7)C(O)(C1-2-alkyl), or -N(R7)2 and is optionally fused to an (un)substituted Ph or (un)substituted cyclohexyl ring; each R7 = H or an (un)substituted C1-3 aliphatic or -N(R7)2 is a N-containing heterocyclyl; each R = H or an (un)substituted C1-6 aliphatic, aryl,

aralkyl, heteroaryl, or heteroaralkylbutyl; and Rx is C1-C8 alkyl.
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:695962 CAPLUS
DN **137:232680**
TI Preparation of aryl and heteroaryl urea selective Chk1 inhibitors for use as radiosensitizers and chemosensitizers for treating diseases and conditions related to DNA damage or lesions in DNA replication
IN Keegan, Kathleen S.; Kesicki, Edward A.; Gaudino, John Joseph; Cook, Adam Wade; Cowen, Scott Douglas; Burgess, Laurence Edward
PA Icos Corporation, USA
SO PCT Int. Appl., 236 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002070494	A1	20020912	WO 2002-US6452	20020301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-273124PP	20010302
US 2003069284	A1	20030410	US 2002-87715	20020301
			US 2001-273124PP	20010302
EP 1379510	A1	20040114	EP 2002-728396	20020301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-273124PP	20010302
			WO 2002-US6452 W	20020301
NO 2003003858	A	20031010	NO 2003-3858	20030901
			US 2001-273124PP	20010302
			WO 2002-US6452 W	20020301

OS MARPAT 137:232680
AB Aryl- and heteroaryl substituted urea compds. (W'NHC(:Y')N(R13)Z'; 1) useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. In 1, W' is a six-membered aromatic ring containing at least 2 nitrogen atoms (e.g. pyrazinyl, pyrimidinyl, pyridazinyl, 1,2,4-triazinyl, quinoxalinyl) and optionally substituted as defined in the claims, Z' is a five- or six membered aromatic or heteroarom. ring as defined in the claims, Y' is O or S. The first claim contains a much more general formula WX1C(:Y)X2Z (e.g. X1 = null, O, S, CH2, NR1; X2 = O, S, NR1) but emphasis is on 1. Methods of making the compds., and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are described. Although the methods of preparation are not claimed, about 200 example prepns. are included. N-(2-methoxy-5-methylphenyl)-N'-(2-pyrazinyl)urea and N-(4-chloro-2-methoxyphenyl)-N'-(2-pyrazinyl)urea enhanced the killing of various human

cells by 5-fluorouracil from 2- to 10-fold; in HeLa cells, these same compds. enhanced killing by irradiation 2-3 fold.
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:457050 CAPLUS
DN **133:79374**
TI Aromatic heterocyclic compounds as thrombin or factor Xa inhibitors
IN Lam, Patrick Yuk Sun; Clark, Charles G.; Li, Hui Yin; Pinto, Donald J. P.
PA Du Pont Pharmaceuticals Co., USA
SO PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039108	A1	20000706	WO 1999-US30512	19991222
	W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1140871	A1	20011010	US 1998-113627PP	19981223
				EP 1999-967485	19991222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				US 1998-113627PP	19981223
	US 6369227	B1	20020409	WO 1999-US30512W	19991222
				US 1999-469830	19991222
	US 6403583	B1	20020611	US 1998-113627PP	19981223
				US 1999-469835	19991222
	JP 2002537227	T2	20021105	US 1998-113627PP	19981223
				JP 2000-591019	19991222
	US 2002115854	A1	20020822	US 1998-113627PP	19981223
	US 6602871	B2	20030805	WO 1999-US30512W	19991222
				US 2001-7195	20011204
	US 6500855	B1	20021231	US 1998-113627PP	19981223
	US 2003004344	A1	20030102	US 1999-469831	B119991222
				US 2002-33137	20020102
				US 1998-113627PP	19981223
				US 1999-469830	A319991222

PATENT FAMILY INFORMATION:
FAN 2000:456883

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000038683	A1	20000706	WO 1999-US30737	19991221
	W: AL, AU, BR, CA, CN, CR, CZ, DM, EE, HU, IL, IN, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TZ, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1998-113627PP	19981223
	CA 2320730	AA	20000706	CA 1999-2320730	19991221
				US 1998-113627PP	19981223

Patel <5/14/2004>

			WO 1999-US30737W	19991221
EP 1058549	A1	20001213	EP 1999-967554	19991221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
			US 1998-113627PP	19981223
			WO 1999-US30737W	19991221
US 6369227	B1	20020409	US 1999-469830	19991222
			US 1998-113627PP	19981223
US 6403583	B1	20020611	US 1999-469835	19991222
			US 1998-113627PP	19981223
US 2002115854	A1	20020822	US 2001-7195	20011204
US 6602871	B2	20030805		
			US 1998-113627PP	19981223
			US 1999-469831	B119991222
US 6500855	B1	20021231	US 2002-33137	20020102
US 2003004344	A1	20030102		
			US 1998-113627PP	19981223
			US 1999-469830	A319991222

FAN 2000:457044

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000039102	A1	20000706	WO 1999-US30735	19991221
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
			US 1998-113627PP	19981223
EP 1140862	A1	20011010	EP 1999-965337	19991221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
			US 1998-113627PP	19981223
			WO 1999-US30735W	19991221
US 6369227	B1	20020409	US 1999-469830	19991222
			US 1998-113627PP	19981223
US 6403583	B1	20020611	US 1999-469835	19991222
			US 1998-113627PP	19981223
US 2002115854	A1	20020822	US 2001-7195	20011204
US 6602871	B2	20030805		
			US 1998-113627PP	19981223
			US 1999-469831	B119991222
US 6500855	B1	20021231	US 2002-33137	20020102
US 2003004344	A1	20030102		
			US 1998-113627PP	19981223
			US 1999-469830	A319991222

OS MARPAT 133:79374

AB This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compns. containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:783653 CAPLUS

DN **128:48065**

TI Preparation of 2-naphthoylguanidines as sodium proton exchanger inhibitors.

IN Brendel, Joachim; Kleemann, Heinz-Werner; Englert, Heinrich Christian; Lang, Hans Jochen; Schwark, Jan-Robert; Weichert, Andreas; Lal, Bansi

PA Hoechst A.-G., Germany
SO Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 810206	A1	19971203	EP 1997-108013	19970516
	EP 810206	B1	20001227		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI				
				DE 1996-19621483A	19960529
	IN 182114	A	19990102	IN 1996-BO205	19960412
				DE 1996-19621483A	19960529
	DE 19621483	A1	19971204	DE 1996-19621483	19960529
	PL 185754	B1	20030731	PL 1997-318723	19970228
				DE 1996-19621483A	19960529
	US 6087304	A	20000711	US 1997-857631	19970516
				DE 1996-19621483A	19960529
	AT 198320	E	20010115	AT 1997-108013	19970516
				DE 1996-19621483A	19960529
	ES 2154002	T3	20010316	ES 1997-108013	19970516
				DE 1996-19621483A	19960529
	PT 810206	T	20010629	PT 1997-108013	19970516
				DE 1996-19621483A	19960529
	AU 9723645	A1	19971204	AU 1997-23645	19970527
	AU 710065	B2	19990916		
				DE 1996-19621483A	19960529
	CN 1167759	A	19971217	CN 1997-113187	19970527
				DE 1996-19621483A	19960529
	TW 416944	B	20010101	TW 1997-86107120	19970527
				DE 1996-19621483A	19960529
	HR 970292	B1	20010831	HR 1997-970292	19970527
				DE 1996-19621483A	19960529
	SK 282020	B6	20011008	SK 1997-670	19970527
				DE 1996-19621483A	19960529
	IL 120924	A1	20020310	IL 1997-120924	19970527
				DE 1996-19621483A	19960529
	CA 2206366	AA	19971129	CA 1997-2206366	19970528
				DE 1996-19621483A	19960529
	NO 9702433	A	19971201	NO 1997-2433	19970528
				DE 1996-19621483A	19960529
	ZA 9704665	A	19971201	ZA 1997-4665	19970528
				DE 1996-19621483A	19960529
	JP 10081664	A2	19980331	JP 1997-138227	19970528
				DE 1996-19621483A	19960529
	RU 2190600	C2	20021010	RU 1997-109003	19970528
				DE 1996-19621483A	19960529
	BR 9703338	A	19980818	BR 1997-3338	19970530
				DE 1996-19621483A	19960529
	GR 3035126	T3	20010330	GR 2000-402772	20001228
				DE 1996-19621483A	19960529

OS MARPAT 128:48065
GI



I

AB Title compds. [I; ≥1 of R1, R3, R4, R5, R6, R7, R8 = XYaWZ, etc.; X = O, S, NR10, CR11R12; R10, R11, R12, R14, R20 = H, alkyl, perfluoroalkyl, cycloalkyl; Y = (heteroatom- or phenylene-interrupted) alkylene; a = 0, 1; W = CH2, SO2, SONH, O, NR14; Z = COR15, SO2R15, NR16R17; R15 = N:C(NH2)2, NR18R19, OR20, etc.; R16, R17, R18, R19 = H, alkyl, perfluoroalkyl; R16R17, R18R19 = (heteroatom-interrupted) alkylene; the rest of R1, R3, R4, R5, R6, R7, R8 = H, F, Cl, Br, iodo, cyano, NO2, CF3, Et, etc.; with provisos], were prepared as antiarrhythmics with cardioprotective activity (no data). Thus, Me 6-hydroxy-2-naphthoate in DMF was treated with NaOMe and then with diethylaminoethyl chloride to give Me 6-(2-diethylaminoethoxy)-2-naphthoate. This was saponified and the acid was condensed with guanidine using CDI to give 6-(2-diethylaminoethoxy)-2-naphthoylguanidine dihydrochloride.

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:684401 CAPLUS
DN **127:346304**
TI Preparation of pyridinioarylcarbamoylindoline derivatives as serotonin receptor antagonists.
IN Bromidge, Steven Mark
PA Smithkline Beecham Plc, UK; Bromidge, Steven Mark
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9737989	A1	19971016	WO 1997-EP1611	19970326
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
			GB 1996-7219	A 19960404
EP 891348	A1	19990120	EP 1997-915465	19970326
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
			GB 1996-7219	A 19960404
			WO 1997-EP1611	W 19970326
JP 2001508399	T2	20010626	JP 1997-535805	19970326
			WO 1997-EP1611	W 19970326
US 6028085	A	20000222	US 1998-155589	19980930
			GB 1996-7219	A 19960404
			WO 1997-EP1611	W 19970326

OS MARPAT 127:346304
AB (R1)nP1A[P2(R2)m]NR3COR4 [R1, R2 = H, (substituted) alkyl; R3 = H, alkyl; R4 = (substituted) N-bonded bicycloheterocyclyl, aminopyrazinyl, aminopyridinyl, aminophenyl, etc.; P1, P2 = Ph, heterocyclyl containing a

quaternary N atom; A = bond, chain of 1-5 atoms (substituted) phenylene, heterocyclylene; n, m = 0-2], were prepared as 5-HT2B/5-HT2C antagonists with increased solubility/activity (no data). Thus, 5-methoxy-6-trifluoromethyl-1-[3-fluoro-5-(pyridin-3-yl)phenylcarbamoyl]indoline in MeCN was treated with sodium tetraphenylboron and bromomethyl acetate followed by 4 h reflux to give a tetraphenylborate salt which was subjected to ion exchange to give 100% 5-methoxy-6-trifluoromethyl-1-[3-fluoro-5-[1-(acetyloxy)methylpyridinium-3-yl]phenylcarbamoyl]indoline chloride.

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:596172 CAPLUS
DN **125:247613**
TI Preparation of indolines as 5-HT2B/2C receptor antagonists
IN Gaster, Laramie Mary; Wyman, Paul Adrian; Mulholland, Keith Raymond; Davies, David Thomas; Duckworth, David Malcom; Forbes, Ian Thomson; Jones, Graham Elgin
PA Smithkline Beecham Plc, UK
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9623783	A1	19960808	WO 1996-EP368	19960126
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE				
			GB 1995-2052	A 19950202
			GB 1995-8327	A 19950425
			GB 1995-8967	A 19950503
			GB 1995-16845	A 19950817
			GB 1995-17542	A 19950826
			GB 1995-18574	A 19950912
CA 2212061	AA	19960808	CA 1996-2212061	19960126
			GB 1995-2052	A 19950202
			GB 1995-8327	A 19950425
			GB 1995-8967	A 19950503
			GB 1995-16845	A 19950817
			GB 1995-17542	A 19950826
			GB 1995-18574	A 19950912
AU 9646646	A1	19960821	AU 1996-46646	19960126
AU 699727	B2	19981210		
			GB 1995-2052	A 19950202
			GB 1995-8327	A 19950425
			GB 1995-8967	A 19950503
			GB 1995-16845	A 19950817
			GB 1995-17542	A 19950826
			GB 1995-18574	A 19950912
			WO 1996-EP368	W 19960126
BR 9607016	A	19971028	BR 1996-7016	19960126
			GB 1995-2052	A 19950202
			GB 1995-8327	A 19950425
			GB 1995-8967	A 19950503

			GB 1995-16845 A 19950817
			GB 1995-17542 A 19950826
			GB 1995-18574 A 19950912
			WO 1996-EP368 W 19960126
EP 808312	A1	19971126	EP 1996-902259 19960126
EP 808312	B1	20001102	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI			
			GB 1995-2052 A 19950202
			GB 1995-8327 A 19950425
			GB 1995-8967 A 19950503
			GB 1995-16845 A 19950817
			GB 1995-17542 A 19950826
			GB 1995-18574 A 19950912
			WO 1996-EP368 W 19960126
CN 1179156	A	19980415	CN 1996-192777 19960126
			GB 1995-2052 A 19950202
JP 10513442	T2	19981222	JP 1996-523247 19960126
			GB 1995-2052 A 19950202
			GB 1995-8327 A 19950425
			GB 1995-8967 A 19950503
			GB 1995-16845 A 19950817
			GB 1995-17542 A 19950826
			GB 1995-18574 A 19950912
			WO 1996-EP368 W 19960126
RO 115522	B3	20000330	RO 1997-1439 19960126
			GB 1995-2052 A 19950202
			GB 1995-8327 A 19950425
			GB 1995-8967 A 19950503
			GB 1995-16845 A 19950817
			GB 1995-17542 A 19950826
			GB 1995-18574 A 19950912
			WO 1996-EP368 W 19960126
AT 197300	E	20001115	AT 1996-902259 19960126
			GB 1995-2052 A 19950202
			GB 1995-8327 A 19950425
			GB 1995-8967 A 19950503
			GB 1995-16845 A 19950817
			GB 1995-17542 A 19950826
			GB 1995-18574 A 19950912
			WO 1996-EP368 W 19960126
ES 2151652	T3	20010101	ES 1996-902259 19960126
			GB 1995-2052 A 19950202
			GB 1995-8327 A 19950425
			GB 1995-8967 A 19950503
			GB 1995-16845 A 19950817
			GB 1995-18574 A 19950912
PT 808312	T	20010330	PT 1996-902259 19960126
			GB 1995-2052 A 19950202
			GB 1995-8327 A 19950425
			GB 1995-8967 A 19950503
			GB 1995-16845 A 19950817
			GB 1995-17542 A 19950826
			GB 1995-18574 A 19950912
PL 184490	B1	20021129	PL 1996-321706 19960126
			GB 1995-2052 A 19950202
			GB 1995-8327 A 19950425
			GB 1995-8967 A 19950503

			GB 1995-16845 A 19950817
			GB 1995-17542 A 19950826
			GB 1995-18574 A 19950912
			WO 1996-EP368 W 19960126
ZA 9600758	A1	19970930	ZA 1996-758 19960131
			GB 1995-2052 A 19950202
IL 116998	A1	20010808	IL 1996-116998 19960201
			GB 1995-2052 A 19950202
			GB 1995-8327 A 19950425
			GB 1995-8967 A 19950503
			GB 1995-16845 A 19950817
			GB 1995-17542 A 19950826
			GB 1995-18574 A 19950912
FI 9703205	A	19971001	FI 1997-3205 19970801
			GB 1995-2052 A 19950202
			GB 1995-8327 A 19950425
			GB 1995-8967 A 19950503
			GB 1995-16845 A 19950817
			GB 1995-17542 A 19950826
			GB 1995-18574 A 19950912
			WO 1996-EP368 W 19960126
NO 9703543	A	19971001	NO 1997-3543 19970801
			GB 1995-2052 A 19950202
			GB 1995-8327 A 19950425
			GB 1995-8967 A 19950503
			GB 1995-16845 A 19950817
			GB 1995-17542 A 19950826
			GB 1995-18574 A 19950912
			WO 1996-EP368 W 19960126
US 5990133	A	19991123	US 1997-875506 19971016
			GB 1995-2052 A 19950202
			GB 1995-8327 A 19950425
			GB 1995-8967 A 19950503
			GB 1995-16845 A 19950817
			GB 1995-17542 A 19950826
			GB 1995-18574 A 19950912
			WO 1996-EP368 W 19960126
HK 1003883	A1	20010831	HK 1998-103018 19980409
			GB 1995-2052 A 19950202
			GB 1995-8327 A 19950425
			GB 1995-8967 A 19950503
			GB 1995-16845 A 19950817
			GB 1995-17542 A 19950826
			GB 1995-18574 A 19950912
			WO 1996-EP368 W 19960126
US 6235758	B1	20010522	US 1999-359606 19990723
			GB 1995-2052 A 19950202
			GB 1995-8327 A 19950425
			GB 1995-8967 A 19950503
			GB 1995-16845 A 19950817
			GB 1995-17542 A 19950826
			GB 1995-18574 A 19950912
			WO 1996-EP368 W 19960126
			US 1997-875506 A319971016
GR 3035075	T3	20010330	GR 2000-402763 20001213
			GB 1995-2052 A 19950202
			GB 1995-8327 A 19950425
			GB 1995-8967 A 19950503

			GB 1995-16845	A 19950817
			GB 1995-17542	A 19950826
			GB 1995-18574	A 19950912
			WO 1996-EP368	W 19960126
US 2003105139	A1	20030605	US 2001-767245	20010122
US 6638953	B2	20031028		
			GB 1995-2052	A 19950202
			GB 1995-8327	A 19950425
			GB 1995-8967	A 19950503
			GB 1995-16845	A 19950817
			GB 1995-17542	A 19950826
			GB 1995-18574	A 19950912
			WO 1996-EP368	W 19960126
			US 1997-875506	A319971016
			US 1999-359606	A319990723

OS CASREACT 125:247613; MARPAT 125:247613

GI



I



II

AB The title compds. [I; P1, P2 = Ph, aromatic or partially saturated monocyclic or bicyclic heterocyclic ring; A = bond, (substituted) C1-5 alkylene, etc.; R1, R2 = H, (substituted) C1-6 alkyl, C2-6 alkenyl, etc.; R3 = H, C1-6 alkyl; R4 = 1-indolinyl, etc.; n, m = 0-2], useful in the treatment of CNS disorders such as anxiety, were prepared Thus, treatment of 3-(3-pyridyl)aniline with 1,1-dicarbonyldiimidazole in CH2Cl2 followed by reaction of the intermediate with 5-methoxy-6-trifluoromethylindoline in DMF afforded 85% the indoline II which showed pKi of 5.8-9.7 against [3H]-mesulergine binding to rat or human 5-HT2C clones expressed in 293 cells in vitro.

=> log y
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	25.40	296.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.85	-5.54

STN INTERNATIONAL LOGOFF AT 08:07:52 ON 14 MAY 2004

Patel <5/14/2004>